The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with ...

FDA advisory panel backs AstraZeneca’s Truqap as the first targeted therapy for PTEN deficient metastatic hormone sensitive prostate cancer. The same panel issues a negative vote on breast cancer drug ...

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option ...

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor ...

Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.

AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks. On May 1, CNBC reported that an FDA advisory panel voted 6-3 against allowing AstraZeneca PLC (NYSE:AZN)’s oral breast cancer drug ...

Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase ...

The revised framework directs drug inspectors to prepare monthly and annual sampling plans covering the entire jurisdiction.